Tempest Therapeutics Inc
TPST
Market Cap$28.2M
Close$
$0.53
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.20 Million |
|---|---|
| Enterprise Value | $21.98 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.5 |
| Beta | -2.33 |
| Outstanding Shares | 3,437,671 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.53 |
|---|---|
| PEG | -1.42 |
| Price to Sales | - |
| Price to Book Ratio | 2.38 |
| Enterprise Value to Revenue | 45.24 |
| Enterprise Value to EBIT | -0.49 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.7 |
| Debt to Equity | 1.37 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Tempest Therapeutics Inc
13 employees
CEO: Julia Owens Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and t...